SMPD3 and Parkinson disease: Currently, DHCer levels have only been evaluated in the plasma of PD patients (Guedes et al., 2017), but given our findings that reducing nSMase2 alleviates the hypoxia-induced DHCer increase, a further evaluation of this lipid in PD brains would be valuable.